[go: up one dir, main page]

PE20160533A1 - Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina - Google Patents

Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina

Info

Publication number
PE20160533A1
PE20160533A1 PE2015001972A PE2015001972A PE20160533A1 PE 20160533 A1 PE20160533 A1 PE 20160533A1 PE 2015001972 A PE2015001972 A PE 2015001972A PE 2015001972 A PE2015001972 A PE 2015001972A PE 20160533 A1 PE20160533 A1 PE 20160533A1
Authority
PE
Peru
Prior art keywords
heparin
monoclonal antibodies
antibodies against
forming complexes
atßh
Prior art date
Application number
PE2015001972A
Other languages
English (en)
Inventor
Frank Dittmer
Uwe Gritzan
Terry Hermiston
Michael Strerath
Jhon E Murphy
Timothy Myles
Ye Jin
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160533(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PE20160533A1 publication Critical patent/PE20160533A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referida a anticuerpos, fragmentos de anticuerpo de union a antigeno (Fabs), y otros andamios de proteina, dirigidos contra antitrombina beta humana que forma complejos con heparina y/o estructura similar a heparina (ATßH). Estas proteinas de union ATßH pueden bloquear la actividad anticoagulante de ATß para inducir coagulacion. Los usos terapeuticos de estos anticuerpos y aglutinantes se describen aqui como lo son los metodos de inmunopurificacion y deteccion especificos de anticuerpos
PE2015001972A 2013-03-14 2014-03-14 Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina PE20160533A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784590P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
PE20160533A1 true PE20160533A1 (es) 2016-06-09

Family

ID=50680168

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001972A PE20160533A1 (es) 2013-03-14 2014-03-14 Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina

Country Status (18)

Country Link
US (4) US9908942B2 (es)
EP (1) EP2970500A1 (es)
JP (1) JP2016519081A (es)
KR (1) KR20150127202A (es)
CN (1) CN105229033B (es)
AR (1) AR095499A1 (es)
AU (1) AU2014236198A1 (es)
BR (1) BR112015021399A2 (es)
CA (1) CA2916421A1 (es)
HK (1) HK1215261A1 (es)
MX (1) MX2015012441A (es)
PE (1) PE20160533A1 (es)
RU (1) RU2015143696A (es)
SG (1) SG11201506886TA (es)
TW (1) TW201529602A (es)
UY (1) UY35457A (es)
WO (1) WO2014153195A1 (es)
ZA (1) ZA201507628B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016519081A (ja) 2013-03-14 2016-06-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ ヘパリンと結合体化した抗トロンビンβに対するモノクローナル抗体
EP3146759B1 (en) * 2014-05-19 2021-04-07 Nokia Solutions and Networks Oy Re-establishment procedure in dual connectivity networks
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP6657392B2 (ja) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
WO2017158176A1 (en) * 2016-03-18 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-antithrombin single-domain antibodies and polypeptides comprising thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5578253A (en) 1978-12-11 1980-06-12 Teikoku Hormone Mfg Co Ltd Immune measurement of hito antithrombin 3
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
BE896543A (fr) 1983-04-22 1983-08-16 Wallone Region Ensembles d'anticorps monoclonaux deriges contre les proteines humaines impliquees dans la coagulation et la fibrinolyse du sang
JPH0644876B2 (ja) 1985-12-13 1994-06-15 株式会社ヤトロン 抗トロンビン・アンチトロンビン３複合体モノクローナル抗体、及びその製造方法、並びにそれを用いるトロンビン・アンチトロンビン３複合体の免疫定量法、及びそれを用いるトロンビン・アンチトロンビン３複合体の精製方法
JPH0266458A (ja) 1988-09-01 1990-03-06 Takara Shuzo Co Ltd ビトロネクチン及びビトロネクチン‐トロンビン‐アンチトロンビン３複合体の測定方法
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU628960B2 (en) 1989-04-07 1992-09-24 Teijin Limited Method of immunologically assaying human thrombin- antithrombin III complex, assay reagent and kit therefor
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
JPH0694713A (ja) * 1991-07-31 1994-04-08 Masashi Funayama アンチトロンビンｉｉｉ活性の測定方法とそれを用いたアンチトロンビンｉｉｉ活性の測定キット
JPH07238099A (ja) 1994-02-25 1995-09-12 Dai Ichi Pure Chem Co Ltd モノクローナル抗体及びこれを用いる免疫学的測定法
FR2718849B1 (fr) 1994-04-14 1996-06-14 Pasteur Sanofi Diagnostics Procédé d'immunodosage de l'antithrombine III activée par un glycosaminoglycane, anticorps monoclonaux correspondants et leur procédé d'obtention.
US5753445A (en) 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
JP3841364B2 (ja) 1994-10-18 2006-11-01 株式会社三菱化学ヤトロン 抗ヒトビトロネクチン・トロンビン・アンチトロンビンｉｉｉ 複合体モノクローナル抗体、ハイブリドーマ及び免疫学的測定方法
DE69738868D1 (de) 1996-05-22 2008-09-11 Viventia Biotech Inc Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
EP0912728A1 (en) 1996-05-31 1999-05-06 MediGene Aktiengesellschaft Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces
WO2000069256A1 (en) 1999-05-13 2000-11-23 Genzyme Transgenics Corp. Transgenically produced antithrombin iii and mutants thereof
JP2001321167A (ja) 2000-05-10 2001-11-20 Cosmo Research Inst モノクローナル抗体
EP2275449B1 (en) 2000-06-16 2016-09-28 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
JP2002316999A (ja) 2001-04-17 2002-10-31 Dai Ichi Pure Chem Co Ltd モノクローナル抗体
US20090226429A1 (en) 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
CA2481401A1 (en) 2002-04-15 2003-10-30 Human Genome Sciences, Inc. Antibodies that specifically bind to tl5
AU2003243381A1 (en) 2002-05-31 2003-12-19 University Of Utah Research Foundation Variants of antithrombin iii
EP1382615A1 (en) 2002-07-15 2004-01-21 Xerion Pharmaceuticals AG MCAM inhibitors
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
RU2262109C2 (ru) 2002-12-30 2005-10-10 Институт биохимической физики им. Н.М. Эмануэля Российской академии наук Способ определения концентрации антитромбина iii в плазме крови
JP4914209B2 (ja) 2003-03-14 2012-04-11 ワイス ヒトｉｌ−２１受容体に対する抗体および該抗体の使用
CA2524737A1 (en) 2003-05-06 2005-02-24 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
GB2404981A (en) 2003-08-15 2005-02-16 Univ Geneve Diagnostic method for stroke
WO2005047331A2 (en) 2003-11-07 2005-05-26 Immunex Corporation Antibodies that bind interleukin-4 receptor
US7271245B2 (en) 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
WO2006017538A2 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
JP4829609B2 (ja) 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
EP1848672A4 (en) 2005-02-01 2009-11-04 Morphosys Ag LIBRARIES AND METHOD FOR ISOLATING ANTIBODIES
ATE539764T1 (de) 2007-07-20 2012-01-15 Univ Paris Sud Xi Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungen
WO2009021754A2 (en) 2007-08-15 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
WO2009073471A1 (en) 2007-11-29 2009-06-11 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
ES2346618B1 (es) 2008-08-14 2011-08-03 Universidad De Murcia Anticuerpo monoclonal anti antitrombina citrulinada humana y sus usos.
NO330078B1 (no) 2008-09-22 2011-02-14 Optipro As Fremgangsmåte og apparat for å overvåke slitasje i sikteduker
US20110311550A1 (en) 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
EP2614084A4 (en) 2010-09-09 2014-02-19 Purdue Research Foundation HUMANE FOLAT RECEPTOR BETA ANTIBODIES AND METHOD FOR THEIR USE
US20140356377A1 (en) * 2011-08-25 2014-12-04 Umc Utrecht Holding B.V. Compounds for use in boosting coagulation
AU2012318242A1 (en) 2011-11-11 2013-05-30 Sio2 Medical Products, Inc. Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus
JP2016519081A (ja) * 2013-03-14 2016-06-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ ヘパリンと結合体化した抗トロンビンβに対するモノクローナル抗体
JP6094713B1 (ja) 2016-06-30 2017-03-15 富士ゼロックス株式会社 定着部材、定着装置、及び画像形成装置

Also Published As

Publication number Publication date
US20160024222A1 (en) 2016-01-28
MX2015012441A (es) 2016-08-08
JP2016519081A (ja) 2016-06-30
US20180244799A1 (en) 2018-08-30
ZA201507628B (en) 2017-11-29
AR095499A1 (es) 2015-10-21
US9908942B2 (en) 2018-03-06
AU2014236198A1 (en) 2015-10-15
US20140271661A1 (en) 2014-09-18
CA2916421A1 (en) 2014-09-25
UY35457A (es) 2014-10-31
CN105229033B (zh) 2019-04-23
BR112015021399A2 (pt) 2017-07-18
KR20150127202A (ko) 2015-11-16
TW201529602A (zh) 2015-08-01
US10144784B2 (en) 2018-12-04
US9593166B2 (en) 2017-03-14
CN105229033A (zh) 2016-01-06
SG11201506886TA (en) 2015-09-29
EP2970500A1 (en) 2016-01-20
WO2014153195A1 (en) 2014-09-25
US20140271660A1 (en) 2014-09-18
RU2015143696A (ru) 2017-04-19
HK1215261A1 (zh) 2016-08-19

Similar Documents

Publication Publication Date Title
CY1125267T1 (el) Antiσωmata eiδiκως σynδeonta pd-1 kai xphσeiς aytωn
DOP2021000013A (es) Proteínas terapéuticas de unión a dll4
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112019010943A2 (pt) métodos para o tratamento do câncer compreendendo agentes de ligação a tigit
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
MX2015016111A (es) Anticuerpos anti-b7-h5 y sus usos.
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
SV2018005659A (es) Anticuerpos agonistas que se unen especificamente a cd40 humanos y metodos de uso
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
EA201890143A3 (ru) Антитела против pdgfr-бета и их применения
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
PE20160533A1 (es) Anticuerpos monoclonales contra antitrombina beta que forma complejos con heparina
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
EA201790438A1 (ru) Антигенсвязывающие белки, которые связываются с cxcr5
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
UY37030A (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
MX380238B (es) Anticuerpos especificos para mmp9.
CY1124445T1 (el) Αντισωματα αντι-ccl17
UY36706A (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
BR112015012414A2 (pt) anticorpos monoclonais contra proteína c ativada (apc)
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.

Legal Events

Date Code Title Description
FD Application declared void or lapsed